Last reviewed · How we verify

NCT05653921

Prospective Study to Validate the Imaging Biomarker for NCP (R33)

Suspended Last updated 7 January 2026
What this trial tests

trial testing In vivo confocal microscopy (IVCM) in Dry Eye Syndromes in 438 participants. Suspended.

Timeline
16 December 2022
Primary endpoint
31 July 2026
31 October 2026

Quick facts

Lead sponsorTufts Medical Center
StatusSuspended
Study typeOBSERVATIONAL
Enrollment438
Start date16 December 2022
Primary completion31 July 2026
Estimated completion31 October 2026
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Tufts Medical Center

Who can join

18 and older, any sex, with Dry Eye Syndromes or Corneal Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is establish the reliability and clinical utility of microneuromas as identified via in vivo confocal microscopy as the diagnostic biomarker for NCP.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Development and validation of a deep learning model for diagnosing neuropathic corneal pain via in vivo confocal microscopy.
    Koseoglu ND, Chen E, Tuwani R, Kompa B, et al · · 2025 · cited 1× · PMID 40369269 · DOI 10.1038/s41746-025-01577-3

Verify or expand the search:

Other recruiting trials for Dry Eye Syndromes

Currently open trials in the same condition.

Other Tufts Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05653921.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing